ACCESS TO ADVANCED HEALTH INSTITUTE
SEATTLE, WASHINGTON 981023797
Top Industries (NAICS)
| NAICS Code | Obligations | Awards |
|---|---|---|
| 541714 | $5.79M | 28 |
| 541715 | $5.02M | 13 |
| 541712 | $-80,840.97 | 2 |
Contract Awards
13 awards found
BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES
THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM.
BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES
THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM.
BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES
THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS.
THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM.
THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM.
BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES
BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES
THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS.
TO SUPPORT THE ADVANCED DEVELOPMENT OF CANDIDATE PRODUCTS, WHICH CONSIST OF A VACCINE COMPONENT IN COMBINATION WITH A DRY FORMULATION TECHNOLOGY
THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS.
Business Details
- UEI
- EMQ1ANLATYS6
- CAGE Code
- 06UF1
- Address
- 1616 EASTLAKE AVE E STE 400
STE 400
SEATTLE, WA 981023797 - Congressional District
- WA-07
- Phone
- 2063810883
Parent Company
ACCESS TO ADVANCED HEALTH INSTITUTE
Data Source
This profile is based on federal contract award data from USAspending.gov.
View on USAspending.gov